Sean Selva
Overview
Explore the profile of Sean Selva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gross P, Duran-Laforet V, Ho L, Melchor G, Zia S, Manavi Z, et al.
Nat Commun
. 2025 Mar;
16(1):2283.
PMID: 40055369
The capacity to regenerate myelin in the central nervous system diminishes with age. This decline is particularly evident in multiple sclerosis (MS), a chronic demyelinating disease. Whether cellular senescence, a...
2.
Gross P, Laforet V, Manavi Z, Zia S, Lee S, Shults N, et al.
bioRxiv
. 2024 Jun;
PMID: 38826296
The capacity to regenerate myelin in the central nervous system (CNS) diminishes with age. This decline is particularly evident in multiple sclerosis (MS), which has been suggested to exhibit features...
3.
Kister I, Curtin R, Piquet A, Borko T, Pei J, Banbury B, et al.
Ann Clin Transl Neurol
. 2024 May;
11(7):1750-1764.
PMID: 38713096
Objectives: (1) To plot the trajectory of humoral and cellular immune responses to the primary (two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple sclerosis (MS) patients up...
4.
Baxter R, Cabrera-Martinez B, Ghosh T, Rester C, Moreno M, Borko T, et al.
Immunohorizons
. 2024 Mar;
8(3):254-268.
PMID: 38483384
The impact of B cell deficiency on the humoral and cellular responses to SARS-CoV2 mRNA vaccination remains a challenging and significant clinical management question. We evaluated vaccine-elicited serological and cellular...
5.
Zhou W, Graner M, Beseler C, Domashevich T, Selva S, Webster G, et al.
Clin Immunol
. 2023 Oct;
256:109801.
PMID: 37816415
We recently reported that multiple sclerosis (MS) plasma contains IgG aggregates and induces complement-dependent neuronal cytotoxicity (Zhou et al., 2023). Using ELISA, we report herein that plasma IgG levels in...
6.
Borko T, Baxter R, Cabrera-Martinez B, Thiruppathi E, Sabalza M, Venkataraman I, et al.
J Neuroimmunol
. 2023 Sep;
383:578192.
PMID: 37666038
Emerging evidence is encouraging and suggests that a substantial proportion of patients without antibody responses (due to anti-CD20 therapy or other etiologies) to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines...
7.
Alvarez E, Nair K, Sillau S, Shelton I, Seale R, Selva S, et al.
Mult Scler J Exp Transl Clin
. 2022 Jan;
8(1):20552173211069359.
PMID: 35024160
Background: Ocrelizumab and rituximab are frequently used treatments for multiple sclerosis (MS). Data on switching from rituximab to ocrelizumab is limited. Objectives: To assess the frequency, severity, and factors of...
8.
Jones D, Alvarez E, Selva S, Gilden D, Nagel M
Neurol Neuroimmunol Neuroinflamm
. 2016 Jun;
3(4):e246.
PMID: 27340684
Objective: To determine the levels of proinflammatory cytokines and matrix metalloproteinases (MMPs) in the CSF of patients with virologically verified varicella zoster virus (VZV) vasculopathy. Methods: CSF from 30 patients...